BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced two oral presentations and a late breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress being held September 7-11, 2024, in Vienna, Austria.

。

The presentations demonstrate the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), to treat all patients with moderate to severe asthma and patients with COPD..

这些演讲证明了Kinaset的主要临床候选药物frevecitinib（KN-002）治疗所有中重度哮喘患者和COPD患者的潜力。。

Kinaset’s leadership team, including Robert Clarke, PhD, co-founder and CEO, Frazer Morgan, co-founder and Chief Development Officer, and Christopher O’Brien, MD, PhD, Chief Medical Officer, will be attending the conference to engage with industry leaders and partners about its innovations in respiratory disease.

Kinaset的领导团队，包括联合创始人兼首席执行官罗伯特·克拉克（Robert Clarke）博士、联合创始人兼首席开发官弗雷泽·摩根（Frazer Morgan）和首席医疗官克里斯托弗·奥布莱恩（Christopher O'Brien）博士，将出席会议，与行业领袖和合作伙伴探讨其在呼吸系统疾病方面的创新。

Dave Singh, M.D., Professor, University of Manchester, Principal Investigator, and a scientific advisor to Kinaset, will be giving the oral presentations..

曼彻斯特大学（University of Manchester）教授、首席研究员、Kinaset科学顾问戴夫·辛格（DaveSingh）医学博士将作口头报告。。

Presentation Details:

演示详细信息：

Oral Presentations

口头陈述

Title: KN-002 reduces fractional exhaled nitric oxide in moderate to severe asthma

标题：KN-002降低中重度哮喘患者呼出一氧化氮的分数

Session Title: Airway diseases therapeutics: novel research studies

会议标题：气道疾病治疗：新的研究

Session Date and Time: Monday, September 9, 9:30 to 10:45

会议日期和时间：9月9日星期一9:30至10:45

Presenter: Dave Singh, M.D., Professor, University of Manchester

主持人：曼彻斯特大学教授、医学博士戴夫·辛格

Location: Lehar 3

地点：莱哈尔

Title: Safety and PK of KN-002 in subjects with moderate to severe asthma using ICS/LABA

标题：使用ICS/LABA治疗中重度哮喘患者KN-002的安全性和PK

Session Title: Recent advances in biological treatments for asthma and chronic obstructive pulmonary disease

课程名称：哮喘和慢性阻塞性肺疾病生物治疗的最新进展

Session Date and Time: Monday, September 9, 14:15 to 15:30

会议日期和时间：9月9日星期一14:15至15:30

Presenter: Dave Singh, M.D., Professor, University of Manchester

主持人：曼彻斯特大学教授、医学博士戴夫·辛格

Location: A1

位置：A1

Late Breaking Poster Presentation

最新发布的海报

Title: The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD

标题：吸入泛JAK抑制剂（KN-002）在COPD患者中的安全性和PK

Session Title: Biological treatments for asthma: novel real-world and clinical studies

课程名称：哮喘的生物治疗：新的现实世界和临床研究

Session Date and Time: Tuesday, September 10, 8:00-9:30

会议日期和时间：9月10日星期二，8:00-9:30

Location: PS-11, Board 18

位置：PS-11，电路板18

About frevecitinib

Frevecitinib

The United States Adopted Name (USAN) Council in consultation with the World Health Organization (WHO)’s International Non-proprietary Names (INN) Expert Committee, has approved the drug name frevecitinib for Kinaset’s lead drug candidate, KN-002. Frevecitinib is a novel, potent and balanced inhibitor of all JAK isoforms (i.e., JAK1, JAK2, JAK3 and TYK2) under development as a non-invasive anti-inflammatory treatment for all patients with eosinophilic and non-eosinophilic asthma inadequately controlled with medium- to high-dose ICS/LABA maintenance treatment plus those with COPD.

美国采用名称（USAN）理事会与世界卫生组织（WHO）的国际非专有名称（INN）专家委员会协商，批准将药物名称frevecitinib作为Kinaset的主要候选药物KN-002。Frevecitinib是一种新型，有效且平衡的所有JAK亚型（即JAK1，JAK2，JAK3和TYK2）抑制剂，正在开发中，作为所有嗜酸性粒细胞和非嗜酸性粒细胞哮喘患者的非侵入性抗炎治疗，中高剂量ICS/LABA维持治疗加COPD患者控制不佳。

Frevecitinib, formulated as a dry powder, has demonstrated excellent delivery efficiency enabling the administration of pharmacologically active doses via a single capsule resulting in therapeutic drug concentrations in lung tissue whilst minimizing systemic exposure levels. A Phase 1 clinical study (NCT05006521), involving 49 healthy volunteers, 55 subjects with mild or moderate to severe asthma and 13 subjects with COPD, has been successfully completed.

配制成干粉的Frevecitinib已经证明具有优异的递送效率，能够通过单个胶囊施用药理活性剂量，从而导致肺组织中的治疗药物浓度，同时最小化全身暴露水平。一项1期临床研究（NCT05006521）已成功完成，涉及49名健康志愿者，55名轻度或中度至重度哮喘患者和13名COPD患者。

A Phase 2b clinical study evaluating frevecitinib in patients with asthma not adequately controlled on medium to high dose ICS/LABA is planned to begin in 2025..

计划于2025年开始一项2b期临床研究，评估在中高剂量ICS/LABA上未得到充分控制的哮喘患者中使用frevecitinib。。

About Kinaset Therapeutics, Inc.

关于Kinaset Therapeutics，Inc。

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.

Kinaset Therapeutics专注于开发吸入疗法，以解决呼吸系统疾病中未满足的重大医疗需求。与5AM Ventures、Atlas Ventures和Gimv的创始投资者一起，该公司正在寻求以患者为中心的方法，以建立一家领先的呼吸治疗公司。

See more information at the Company’s website..

有关更多信息，请访问公司网站。。